Endeavor Biomedicines, Inc.

Taurus Biosciences, LLC

Biomed Realty, L.p.

Miguel De Los Rios

John Hood

Luis A Dellamary

Anita Difrancesco

Omar A Bazirgan

Stephanie De Los Rios

Anita J DiFrancesco

Jacek Ostrowski

Paul A Frohna

Kenneth J Oh

Ilan Zipkin

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

Methods of improving lung function

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

Methods of treating fibrosis

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

Method of treating fibrosis

The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 and uses thereof.

Humanized antibodies with ultralong complementary determining regions

Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule. Also disclosed are particles and compositions that include the disclosed chimeric therapeutics.

Chimeric therapeutics, compositions, and methods for using same

Provided herein are methods and compositions for controlling assembly of modified viral core proteins, for example, into a viral capsid or a nanocage. In some embodiments, the disclosed modified viral core proteins comprise at least one mutation or modification that can substantially prevent assembly of the viral core proteins until assembly is desired. In some embodiments, assembly of the viral core proteins may be triggered, for example, by contacting the viral core proteins with a reducing agent and/or by reducing the concentration of a denaturant. The viral core proteins may self-assemble to form a viral capsid or nanocage.

Growing community of inventors

Del Mar, CA, United States of America

Miguel De Los Rios